Survival Trends for Patients with Small Cell Lung Cancer (SCLC) in the United States: Analysis of the SEER Database
- 1. Department of Population Health Science, Augusta University, Augusta, USA
- 2. Department of Internal Medicine, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, USA
Background: Small cell lung cancer (SCLC) generally has poor outcomes. The last thirty years have seen some improvement in management options for these patients, but their impact on the general population is unclear.
Objective: The present study analyzed trends in the diagnosis and survival of SCLC patients between 1988 and 2015.
Method: The Surveillance, Epidemiology, and End Result (SEER) registry was used to identify SCLC cases from 1988 to 2015. Patients were classified as having either limited stage (LS) or extensive stage (ES) disease. Cox regressions were used to compare overall survival (OS).
Results: We analyzed 98,281 SCLC patients. More males were diagnosed with ES-SCLC and had worse OS compared to females (HR: 1.14 [CI 1.11- 1.16]). Although younger patients had higher proportion of ES-SCLC diagnosis, the older patients had worse OS for both stages (LS-SCLC: HR 1.36 [CI 1.32- 1.40]; ES-SCLC: HR: 1.34 [CI 1.31-1.36]). Among LS-SCLC, Blacks had worse OS compared to Whites (LS-SCLC: HR 1.06 [CI 1.02-1.10]) and no differences in OS in ES-SCLC among races. Compared to the reference period 1988-1992, patients diagnosed with ES-SCLC during the later periods had improved OS: 1998-2002 (HR: 0.97 [CI, 0.94-1.00]), 2003- 2007 (HR: 0.92 [CI 0.90-0.95]), 2008-2012 (HR: 0.91 [CI 0.88- 0.94]), and 2013-2015 (HR: 0.91 [CI 0.88- 0.94]).
Conclusion: Females, Whites, and younger patients with SCLC had better OS compared to males, Blacks, and older patients. The results show increase in OS of SCLC patients over time, particularly for those with LS-SCLC.
Monirul Islam KM, Stevens A, Ganti AK (2020) Survival Trends for Patients with Small Cell Lung Cancer (SCLC) in the United States: Analysis of the SEER Database. JSM Clin Oncol Res 8(1): 1062.
- Small cell lung cancer
Lung cancer is the leading cause of cancer-relateddeaths in the United States (U.S.) . According to the American Cancer Society estimate for 2019, there will be 228,150 new cases of lung cancer and 142,670 associated deaths . Approximately 80% to 85% of lung cancer cases are non-small cell lung cancer (NSCLC); small cell lung cancer (SCLC) accounts for 13% of cases [2,3]. Although, the incidence of SCLC has decreased in the past two decades, mortality remains high [3-5]. SCLC follows an aggressive course and tends to metastasize early; hence, about 70% of patients are diagnosed with an extensive stage (ES) [4,6]. The last thirty years have seen limited improvements in options available for these patients, namely the use of platinum-etoposide as the primary chemotherapy option, use of thoracic radiation for patients with limited-stage (LS)- SCLC, addition of prophylactic cranial irradiation following initial therapy, and approval of topotecan as a salvage regimen [7-12]. However, the impact of these advances on outcomes in the general population is unclear. The purpose of this analysis was to examine the survival trend of SCLC patients.
Data from the Surveillance, Epidemiology, and End Result (SEER) 18 Registry Research Database (1975-2015) was used to determine patient characteristics and survival for SCLC. SEER 18 collects data from 18 population-based cancer registries of the U.S., which represents about 28% population of the country.
The ES-LS system is used to determine management decisions and was used in the present analysis. In addition, this system has not changed despite the changes in the more conventional American Joint Committee on Cancer (AJCC) system. Limited stage (LS) is typically defined as disease that can be encompassed in a single radiation field, whereas extensive stage (ES) is that not encompassed within a single radiation field [13,14]. Thus, LS-SCLC generally corresponds to AJCC stages I to III, whereas ES-SCLC corresponds to AJCC stage IV . Patients with unknown stage or occult stage were excluded.
Study cohort and variables
Site codes C34.0-C34.9 were used to extract information for lung and bronchial cancer for years 1988 to 2015. Histology codes 8041 to 8045 designated for SCLC in the SEER database were used. The 3rd and 6th edition of the AJCC staging was used to encompass all the years analyzed. Patients who were <20 years of age, had missing information, unknown survival time or a zero in survival month were excluded. Patients with zero survival months were excluded because we could not determine if it was due to loss to follow up or if the patient died on or near the day of diagnosis. The SEER variable vital status was used as the censoring variable. The variables analyzed for both stages, LS-SCLC and ES-SCLC, included age at diagnosis, gender, race, and year of diagnosis.
To examine changes in survival pattern, year of diagnosis (YOD) was grouped into six intervals: 1988-1992, 1993- 1997, 1998-2002, 2003-2007, 2008-2012, and 2013-2015. Age at diagnosis was grouped into two categories: age ≤ 70 and >70. The race was grouped into White, Black and Other. ES-SCLC and LS-SCLC were created by merging the variables from the 3rd and 6th editions of the AJCC into one variable, and then recoded as dichotomous: 1-3 were made into LS-SCLC and 4 is ES-SCLC.
Descriptive statistics used frequency distributions to determine the feature that predicted survival of SCLC patients. Overall survival (OS) for different variables was compared using Kaplan-Meier curves with log-rank statistics. We used Cox proportional-hazard regressions to examine the association of age at diagnosis, gender, race, and YOD with hazard ratios of death for patients with LS-SCLC or ES-SCLC. A p-value <0.05 was considered statistically significant. All statistical analyses were performed with SPSS software version 25 (Armonk, NY: IBM Corp.).
The analysis was performed on 98,281 patients who were diagnosed with SCLC between 1988 and 2015, after excluding patients with occult stage or unknown stage, and those who had missing or incomplete information on survival month. Most cases were diagnosed as ES compared to LS (61% vs. 39%). The median survival for the SCLC varied by stages (LS 12 vs. ES 7 months), when no other predictors were included in the models.
Females were more likely to be diagnosed with LS disease than males (52.7% vs 47.3%). Both SCLC stages had a higher proportion of younger (≤ 70) compared to older patients (>70) (LS- SCLC: 57.5% vs 42.5%, p<.0001; ES-SCLC: 60.2% vs 39.8%, p<.0001).
Further analysis adjusted for predictor variables, such as sex, age, race, and year of diagnosis. Kaplan-Meier survival estimates showed that median OS for younger patients was higher compared to older patients for LS-SCLC (15 vs. 10 months, p<.0001) and for ES-SCLC (8 months vs. 5 months; p<.0001) (Table 1). Older patients with LS-SCLC had a 1.36-fold increased risk of death (95% CI: 1.32-1.40, p<.0001) when compared to younger patients; for ES disease the risk was 1.34 times higher (95% CI: 1.31-1.36, p<.0001).
Median OS for whites with LS was 13 months compared to 12 months for blacks and other races; however, this was not significant (Table 3). The median survival for all races with ESSCLC was 7 months (p<.01) (Table 3). The hazard of death due to LS-SCLC was not different for White and Other race categories (Table 2), but Black patients with LS had 6% increased risk of death compared to Whites (95% CI: 1.02-1.10, p<.001). However, for ES-SCLC, there was a significant difference between White and Other (HR: .99, 95% CI: .87-.95, p<.0001), but no significant differences between White and Black.
The OS rates for LS and ES-SCLC patients varied by gender. Females with LS-SCLC disease had a better median survival compared to males (13 vs 12 months, p-value <.0001) (Table 3). Median survival for females and males with ES-SCLC was 7 months (p<.0001) (Table 3). Males had a higher risk of death compared to females in the LS group (HR: 1.14, 95% CI: 1.11- 1.16, p<.0001) and the ES group (HR: 1.15, 95% CI: 1.13- 1.17, p<.0001) (Table 2).
Multivariate analysis showed that the survival improved over time for both LS and ES-SCLC during the study period. Using the years 1988-1992 as the reference, LS-SCLC in years 1993- 1997 HR: 0.96 (CI: 0.91-1.00, p<.05) reduced to HR: 0.80 (CI: 0.72- 0.80, p<.0001) in years 2013- 2015; ES-SCLC in years 1993-1997 HR: 0.97 (CI: 0.93-1.01, p<.137) reduced to HR: 0.91 (CI: 0.88- 0.94, p<.0001) in years 2013-2015 (Table 2).
Table 1: Descriptive statistics of study population for SCLC, 1988-2015.
|LS N=38,182 n (%)||ES N=60,099 n (%)|
|Gender||Female||20,123 (52.7)||28,157 (46.9)|
|Male||18,059 (47.3)||31,942 (53.1)|
|Age at diagnosis||≤70||21,949 (57.5)||36,172 (60.2)|
|>70||16,233 (42.5)||23,927 (39.8)|
|Race||White||32,933 (86.3)||52,755 (87.8)|
|Black||3543 (9.3)||5032 (8.4)|
|Others||1683 (4.4)||2276 (3.8)|
|Year of diagnosis||1988-1992||2844 (7.4)||5141 (8.6)|
|1993-1997||3.912 (10.2)||5868 (9.8)|
|1998-2002||7074 (18.5)||10,487 (17.4)|
|2003-2007||9654 (25.3)||14,255 (23.7)|
|2008-2012||9251 (24.2)||15,136 (25.2)|
|2013-2015||5447 (14.3)||9212 (15.3)|
|Abbreviations: SCLC: Small Cell Lung Cancer; LS: Limited Stage; ES: Extensive stage. The differences between the two stages for all variables were significant (p=.0001).|
About 61% of the study population was diagnosed with ES. The findings are consistent with other reports and national estimates [1,16]. The results show little improvement in early detection of SCLC. Challenges from the natural history of the disease, lack of early detection methods, and limited molecular profiling are factors related to the high proportion of SCLC patients diagnosed as ES [6,17,18]. The rapid growth and high malignancy of SCLC have caused difficulties in cancer detection [13,17]. To date, there has been no effective approach for early detection of SCLC as compared to NSCLC [6,18]. For NSCLC, the development of early detection methods have resulted in improved disease outcomes . Unfortunately, early detection using CT screening has not resulted in an improvement in survival from SCLC . These factors have contributed to the relatively unchanged therapeutic options over the past decades .
Despite the poor prognosis associated with SCLC, there has been little improvement in treatment over the past two decades. Chemotherapy with a platinum compound and etoposide is the main treatment for this disease . Patients with LS-SCLC are generally treated with a combination of chemotherapy and radiation. A meta-analysis of 2,013 patients showed that, for LS-SCLC,the combination of radiation with chemotherapy translated into an absolute survival benefit of 5.4% at 3 years with a relative risk of death of 0.86 (95% CI, 0.78-0.94) . Another meta-analysis of 1,524 patients showed that early initiation of radiation improved the 2-year survival rate with an OS relative risk of 1.17 (95% CI, 1.02-1.35) . Both LS and ES-SCLC patients are at increased risk of brain metastasis relative to other types of lung cancer [14,22]. SCLC patients (including ES-SCLC patients in some analyses) who were treated with prophylactic cranial irradiation (PCI) have better survival outcomes and reduced risk of brain metastasis compared to SCLC patients not treated with PCI [23,24].
Results from the present analysis reflect the minimal improvement in treatment outcomes over the decades for either of the stages of SCLC, which is consistent with two previous studies that used SEER database, showing improved or moderately improved survival [3,25]. Govindan et al., estimated survival using a short follow-up time , the present study had a longer follow-up period, which could result in a different mortality risk. In addition, our study used data that are more recent from the SEER registry, which has higher population coverage.
In general, the present results, obtained with a large population-based database, demonstrated some improvement in survival over time. ES patients showed steady improvements throughout, while those with LS experienced an increased risk in those diagnosed between 1993 and 1998, but later improved through 2015. Moreover, more than 40% of patients in our cohort did not have any information about treatment. It is unclear as to how many of these patients were not recommended for treatment, refused treatment, or received suboptimal therapy. Since data regarding receipt of chemotherapy and detailed information about radiation (e.g., PCI, timing of radiotherapy) are unavailable in the SEER dataset, it is unclear if the minimal improvement in outcomes is due to non-receipt of recommended therapy or due to a lack of appreciable benefit. Nonetheless, the trend is promising and as more advancements in treatments and technology enter the field, SCLC outcomes may see further gains. However, since population-based data describing the trend of treatment utilization in the U.S. are limited, it is difficult to associate treatment patterns and outcomes in a real-world setting. A large hospital-based study in the U.S. reported increased use of chemo-radiation for LS-SCLC patients, but the 5-year survival rate for these patients did not increase appreciably . Another study using SEER-Medicare data showed a modest survival benefit over time among SCLC patients who received chemotherapy, but the finding was not statistically significant . A hospital-based study in the United Kingdom suggested that, although there is an upward trend in the receipt of chemo-radiation, the small increase does not substantially affect the OS .
In the last three decades, there has been an increase in the proportion of females with SCLC [3,5]. Our analysis also found a higher number of females with a diagnosis of LS-SCLC compared to males. Smoking is the leading cause for SCLC, being responsible for more than 90% of cases. Secondhand smoke increases the risk of developing any kind of lung cancer by 30% [2,3]. The higher numbers of females with SCLC can be attributed to increased prevalence of smoking in this population.
The present results are in agreement with those of other studies indicating that female SCLC patients have better survival outcomes compared to males [3,29,30]. Females have a better prognosis for LS-SCLC as well [30,31]. The reason for this difference is unclear . A study at the National Cancer Institute shows a median survival of 13 months for females compared to 10 months for males for LS-SCLC; other studies conducted by the Cancer and Leukemia Study Group B (CALGB) and Southwest Oncology Group (SWOG) have similar findings [32,33].
With increasing age, survival for SCLC is decreased [34,35]. In accordance with previous studies, we found that overall survival outcomes were worse for older (≥70 years) SCLC patients. The reason for worse survival of older patients may be because of more comorbidities, reduced organ function, or organ failure [36,37]. The combination of reduced performance status, co-morbidities, and elevated risk for toxicities causes older patients to receive less aggressive treatment and to be withdrawn from treatment . However, elderly patients who can tolerate toxicity from chemotherapy show similar survival relative to younger patients . Thus, it is necessary to identify which elderly patients can tolerate intensive treatment. Our findings show that, compared to Whites, African Americans have a higher risk of dying from SCLC. Previous studies show that this disparity in outcomes is partly because African American patients are diagnosed at an advanced stage [39,40]. The lower socio-economic status and limited access to health care could be factors that prevent African Americans from receiving timely treatment [39,40]. A study of NSCLC using the SEER Medicare database shows that, compared to whites, African Americans often do not receive proper staging, and, even if they are staged properly, are less likely to receive appropriate treatment . Another study using Veterans Affairs Central Cancer Registry data on NSCLC shows that, compared to Whites, the proportion of African Americans not receiving appropriate staging is higher . However, these studies and others show that if African Americans get proper staging and treatment, after adjusting for socio-economic factors, survival is not different and may be slightly better compared to whites [41-43].
Limitations of the present study include lack of information on the provision of chemotherapy and reasons for not administering radiotherapy. In the study cohort, a large proportion of patients did not receive radiation, but we could not determine if these patients were treated with chemotherapy alone. This limitation made us unable to analyze the impact of treatment on survival. However, the information represents the care received by patients in a real-world setting. Hence, we feel that the findings serve to underline the differences in the efficacy of management approaches.
In conclusion, there has been some improvement in outcomes for SCLC patients in this population-based database, which is in line with advances in SCLC outcomes in clinical trials. We should consider whether there is racial bias in providing and receiving treatment and an effort should be made to provide standard care to all patients irrespective of their race, ethnicity, and gender.
Table 2: Multivariate analysis of factors affecting survival in SCLC by stages.
|HR (95% CI)||p-value||HR (95% CI)||p-value|
|Male||1.14 (1.11, 1.6)||<0.0001||1.15 (1.13,1.17)||<.0001|
|>70||1.36 (1.32, 1.40)||<0.0001||1.13 (1.31, 1.36)||<.0001|
|Black||1.06 (1.02, 1.10)||0.004||1.02 (0.99,1.05)||0.242|
|Others||0.97 (0.93, 1.03)||0.318||0.99 (0.87, 0.95)||<.0001|
|Year of diagnosis||1988-1992||ref||ref|
|1993-1997||0.96 (0.91, 1.00)||0.062||0.97 (0.93, 1.01)||0.137|
|1998-2002||0.98 (0.89, 0.97)||0.001||0.97 (0.94, 1.00)||0.05|
|2003-2007||0.86 (0.83, 0.90)||<0.0001||0.92 (0.90, 0.95)||<.0001|
|2008-2012||0.81 (0.78, 0.85)||<0.0001||0.91 (0.88, 0.94)||<.0001|
|2013-2015||0.80 (0.72, 0.80)||<0.0001||0.91 (0.88,0.94)||<.0001|
|Abbreviations: SCLC: Small Cell Lung Cancer; LS: Limited Stage; ES: Extensive Stage. P-value was set at 0.05|
Table 3: Kaplan Meier median survival estimates by SCLC stages.
|Median Survival (Months)||p-value||Median Survival (Months)||p-value|
|Abbreviations: LS: Limited Stage; ES: Extensive Stage. P-value was set at 0.05.|
1. Siegel RD, Naishadham, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. American Cancer Society. Cancer Facts & Figures. 2019. Atlanta: American Cancer Society. 2019.
3. Govindan R, Page N, Morgensztern D, Read W, Terney R, Wlahotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24: 4539-4544.
4. de Hoyos A, DeCamp MM. Surgery for Small Cell Lung Cancer. Thoracic Surgery Clinics. 2014; 24: 399-409.
5. Riaz SP, Lüchtenborga M, Couplanda VH, Spicerb J, Peakec MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012; 75: 280-284.
6. Byers LA, Rudin CM. Small cell lung cancer: Where do we go from here? Cancer. 2014; 121: 664-672.
7. Aupérin A, Arriagada R, Pignon JP, Péchoux CL, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. NEJM. 1999. 341: 476-484.
8. Meert AP, Paesmans M, Sculier JP. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC cancer. 2001; 1: 5.
9. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer. NEJM. 1992; 327: 1618-1624.
10. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small- cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10: 282-291.
11. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658-658.
12. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A metaanalysis. J Clin Oncol. 1992; 10: 890-895.
13. Kurup A, Hanna NH. Treatment of small cell lung cancer. Critical reviews in oncology/hematology, 2004; 52: 117-126.
14. Ganti AK. Current concepts in the management of small cell lung cancer. Indian journal of medical research (New Delhi, India : 1994), 2013; 137: 1043-1051.
15. Rami-Porta R, Crowley JJ, Goldstraw P. Review the revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009; 15: 5.
16. Parsons HM. Treatment of Small Cell Lung Cancer in Academic and Community Settings Factors Associated With Receiving Standard Therapy and Survival. The cancer journal (Sudbury, Mass.). 2014; 20: 97-104.
17. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of Small Cell Lung Cancer. Chest. 2013; 143: e400S-e419S.
18. Pietanza MC, Byers LA, Minna JD, Rudin CM. Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes? Clin Cancer Res. 2015; 21: 2244-2255.
19. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013; 119: 3976-3983.
20. Pillai RN, Owonikoko TK. Small Cell Lung Cancer: Therapies and Targets. Seminars in Oncology. 2014; 41: 133-142.
21. Fried DB. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22: 4837-4845.
22. Hochstenbag MM. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000; 48: 243-248.
23. Aupérin A, Arriagada R, Pignon JP, Péchoux CL, Gregor A, Stephens RJ, et al. Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission. NEJM. 1999; 341: 476-484.
24. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. NEJM. 2007; 357: 664-672.
25. Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009. 64: 226-231.
26. Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer. 2005; 6: 355- 360.
27. Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE, et al. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer. 2016; 122: 50-60.
28. Khakwani A, Rich AL, Tata LJ, Powell HA, Stanley RA, Baldwin DR, et al. Small-cell lung cancer in England: trends in survival and chemotherapy using the National Lung Cancer Audit. PLoS One. 2014.
29. Johnson BE. Female patients with small cell lung cancer live longer than male patients. Am J Med. 1988; 85: 194-196.
30. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991; 63: 986-992.
31. Østerlind K. Prognostic Factors in Small Cell Lung Cancer: An Analysis of 874 Consecutive Patients, in Lung Cancer: Basic and Clinical Aspects, H. Hansen, Editor. 1986; 129-152.
32. Albain KS. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990; 8: 1563-1574.
33. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol. 1989; 7: 344-354.
34. Janssen-Heijnen MLG, AAMMaasc Huub, Koningd CaroCE, Bruggen-Bogaartse Brigitte AHA, van der, Groenf Harry JM, et al. Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer. J Geriatric Oncol. 2014; 5: 71-77.
35. Ludbrook JJS, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys. 2003; 55: 1321-1330.
36. Maas HAAM, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive Geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007; 43: 2161-2169.
37. Lees J. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011; 12: 1249-1257.
38. Johnson DH. Small cell lung cancer in the elderly patient. Sem Oncol. 1997; 24: 484-491.
39. Biswas T, Walker P, Podder T, Rosenman J, Efird J. Important prognostic factors for lung cancer in tobacco predominant Eastern North Carolina: Study based on a single cancer registry. Lung Cancer. 2014; 84: 116-120.
40. Brawley OW. Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. J Clin Oncol. 2006; 24: 332- 333.
41. Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol. 2006; 24: 413- 418.
42. Ganti AK, Subbiah SP, Kessinger A, Gonsalves WI, Silberstein PT, Loberiza FR Jr. Association Between Race and Survival of Patients With Non–Small- Cell Lung Cancer in the United States Veterans Affairs Population. Clin Lung Cancer. 2014; 15: 152-158.
43. Blackstock AW. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. JNCI. 2002; 94: 284- 290.